Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 20/20 | 0.88 |
| ▸ | BCL2 | P10415 | 15/20 | 0.88 |
| ▸ | ALB | P02768 | 1/20 | 0.80 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4465505 | 0.98 | BCL2L1 (0.88) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL2949972 | 0.94 | BCL2L1 (1.00) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL6795563 | 0.92 | BCL2L1 (0.77) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL2951265 | 0.92 | BCL2L1 (0.87) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL2943308 | 0.92 | BCL2L1 (0.87) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL2945317 | 0.92 | BCL2L1 (0.83) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL4477794 | 0.92 | BCL2L1 (0.86) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL2944986 | 0.92 | BCL2L1 (0.76) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL2952018 | 0.91 | BCL2L1 (0.88) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL2951511 | 0.91 | BCL2L1 (0.76) | BCL2L1BCL2ALBBCL2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3331546-B1 | CXCR4 INHIBITOR FOR THE TREATMENT OF CANCER | BIOKINE THERAPEUTICS LTD (IL) | 2023-10-04 | — | — | EP | claimed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | claimed |
| US-20250367287-A1 | COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR | GENENTECH, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250152582-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR | GENENTECH, INC. (US) | 2025-05-15 | — | — | US | disclosed |
| CN-113607945-B | Combination therapy of anti-HER 2 antibody-drug conjugates and Bcl-2 inhibitors | 豪夫迈·罗氏有限公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20240423979-A1 | THERAPEUTICALLY EFFECTIVE COMBINATION OF A FLT3 INHIBITOR AND A BCL-2 INHIBITOR FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA | HANMI PHARM. CO., LTD. (KR) | 2024-12-26 | — | — | US | disclosed |
| EP-4419106-A1 | THERAPEUTICALLY EFFECTIVE COMBINATION OF A FLT3 INHIBITOR AND A BCL-2 INHIBITOR FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA | Hanmi Pharm. Co., Ltd. (KR) | 2024-08-28 | — | — | EP | disclosed |
| US-20240277838-A1 | COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR | GENENTECH, INC. (US) | 2024-08-22 | — | — | US | disclosed |
| CN-118510517-A | Therapeutically effective combination of FLT3 inhibitor and BCL-2 inhibitor for the treatment of acute myeloid leukemia | 韩美药品有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20240108616-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR | GENENTECH, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240000776-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR | GENENTECH, INC. (US) | 2024-01-04 | — | — | US | disclosed |
| US-7754886-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090098118-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | ROCHE GLYCART AG (CH) | 2009-04-16 | — | — | US | disclosed |
| US-7504512-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1318978-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | ABBVIE INC. | 2004-09-30 | — | — | US | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | BCL2L1 5/4885BCL2 3/4885ALB 4765/4885 |
| US-20240277838-A1 | COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR | ERBB2, BAK1, BCL2L2 | BCL2L1 6/4885BCL2 4/4885ALB 1830/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | BCL2L1 4/4885BCL2 3/4885ALB 4718/4885 |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | BCL2L1 5/4885BCL2 3/4885ALB 4765/4885 |
| US-20240108616-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR | BCL3, BAK1, BCL2L13 | BCL2L1 7/4885BCL2 4/4885ALB 4415/4885 |
| US-20250367287-A1 | COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR | ERBB2, BAK1, BCL2L2 | BCL2L1 6/4885BCL2 4/4885ALB 1830/4885 |
| US-20250152582-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR | BCL3, BAK1, BCL2L13 | BCL2L1 7/4885BCL2 4/4885ALB 4415/4885 |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BCOR | BCL2L1 6/4885BCL2 2/4885ALB 4581/4885 |
| US-20240423979-A1 | THERAPEUTICALLY EFFECTIVE COMBINATION OF A FLT3 INHIBITOR AND A BCL-2 INHIBITOR FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA | MCL1, FLT3, BCL2 | BCL2L1 8/4885BCL2 3/4885ALB 4111/4885 |
| US-20240000776-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR | BCL3, BAK1, BCL2L13 | BCL2L1 7/4885BCL2 4/4885ALB 4415/4885 |
| US-20090098118-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | BAK1, BCL2, BCL3 | BCL2L1 7/4885BCL2 2/4885ALB 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.